c HIV-1 drug resistance (HIVDR) assays are important tools in clinical management of HIV-infected patients on antiretroviral therapy (ART) and surveillance of drug-resistant variants at population levels. The high cost associated with commercial assays hinders their use in resource-limited settings. We adopted and validated a low-cost in-house assay using 68 matched plasma and dried blood spot (DBS) samples with a median viral load (VL) of 58,187 copies/ml, ranging from 253 to 3,264,850 against the commercial assay ViroSeq. Results indicated that the in-house assay not only had a higher plasma genotyping rate than did ViroSeq (94% versus 78%) but also was able to genotype 89.5% (51/57) of the matched DBS samples with VLs of >1,000 copies/ml. The sensitivity in detecting DR mutations by the in-house assay was 98.29% (95% confidence interval [CI], 97.86 to 98.72) on plasma and 96.54 (95% CI, 95.93 to 97.15) on DBS, and the specificity was 99.97% (95% CI, 99.91 to 100.00) for both sample types compared to ViroSeq. The minor DR mutation differences detected by the in-house assay against ViroSeq did not result in clinical significance. In addition, cost analysis showed that the in-house assay could reduce the genotyping cost by about 60% for both plasma and DBS compared to ViroSeq. This field condition evaluation highlights the potential utility of a cost-effective, subtype-independent, in-house genotyping assay using both plasma and DBS specimens for HIVDR clinical monitoring and population-based surveillance in resource-limited settings.
T
here has been a tremendous increase in antiretroviral therapy (ART) in sub-Saharan Africa and other developing countries, largely due to the increased support by various multinational groups, such as the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) and the Global Fund to Fight AIDS, Tuberculosis and Malaria (1) (2) (3) (4) . This has resulted in the significant reduction of HIV/AIDS-related morbidity and mortality among the 1.6 million patients currently on ART in the sub-Saharan region (1, 4) . The long-term success of these ART programs, however, requires adequate monitoring of ART patients to ensure favorable treatment outcomes and minimize the development and transmission of HIV drug resistance (HIVDR), given the limited antiretroviral (ARV) drug regimen choices available in these settings (5) (6) (7) . The cost and logistics involved in assays that are used to monitor HIVDR in ART patients remain challenging in resource-limited settings (5, 8, 9) . Several initiatives are under way to establish alternative, less costly methods for laboratory-based ART patient monitoring, such as point-of-care CD4 testing, semiquantitative HIV viral load (VL) testing, and HIVDR testing using dried blood spots (DBS) (10) (11) (12) (13) (14) (15) (16) . These parameters are routinely used in assessing treatment responses in resource-rich countries. HIVDR tests for patients on ART are not only important in monitoring individual patient treatment outcomes but also essential as public health tools in the routine assessment of the spread of drug-resistant variants at population levels (5, (17) (18) (19) . Such data are vital in guiding a country's ARV drug regimen implementation strategy and in forecasting the need for new ARV drugs, especially in resource-limited settings where treatment options are limited (20) (21) (22) .
Currently, there are two HIV-1 genotyping systems approved by the U.S. Food and Drug Administration (FDA), ViroSeq (Abbott Molecular, Abbott Park, IL) and TruGene (Siemens Healthcare Diagnostics, Deerfield, IL). These commercial systems are costly and were designed and approved to genotype HIV-1 subtype B viruses, which makes them less sensitive in genotyping HIV-1 variants in geographic areas where non-B subtypes and circulating recombinant forms (CRFs) are predominant (23, 24) .
The preferred sample type used in these assays is either plasma or serum. This type of sample requires cold-chain conditions for collection, transportation, and storage (23) as well as separation of plasma from whole blood within 6 h of blood collection. In addition, venous blood collection requires well-trained phlebotomists and poses a potential risk to health care workers for occupational HIV exposure from needle sticks. In resource-limited settings, inadequate health care infrastructure often necessitates the collection of blood samples from peripheral sites and transport to a reference facility where processing of samples and testing are carried out. These logistical issues make the conventional plasma specimen collection nonideal for use in such settings. DBS offer an alternative specimen type to overcome these challenges: DBS do not require large amounts of blood and can be collected easily by finger or heel prick with minimal preprocessing procedures or risk to the health care worker. Moreover, they are easier to transport and store, do not require cold-chain transportation, and can be stored at ambient temperature for up to 2 weeks without compromising the genotyping efficiency (25, 26) . Once air dried and properly packaged, they are considered noninfectious (27) .
In order to mitigate the high cost associated with commercial genotyping tests and streamline the sample collection process, there have been systematic efforts to develop and evaluate inhouse assays and adopt the assays for use with the DBS sample type, and several assays have shown promising results (24, (28) (29) (30) . With the publication of the WHO manual for HIV drug resistance testing using dried blood spot specimens in 2010 and the promising results obtained from the in-house genotyping assays (31), we initiated a study to adopt and validate a broadly sensitive in-house assay (32, 33) against the FDA-approved ViroSeq HIV-1 drug resistance genotyping system using both plasma and DBS specimens.
MATERIALS AND METHODS
Study population. Plasma and DBS samples were obtained from HIV-1-positive mothers and children enrolled in the Kisumu Breastfeeding Study (KiBS), which assessed the efficacy of combined ART, mainly either nevirapine (NVP) with zidovudine (AZT) and lamivudine (3TC) or nelfinavir (NFV) with AZT and 3TC given from 34 weeks into the gestation period through 6 months postpartum for the prevention of mother-to-child transmission (PMTCT) (34) . These included 39 samples from mothers collected at 6 months postpartum after at least 6 months on ART and 29 samples from infants exposed to maternal ART through breast milk. The VL of these specimens ranged from 253 to 3,264,850 copies/ml. We also included seven DBS samples from a proficiency panel which were used to assess the reproducibility of DBS. These were replicates from a 14-member panel from the virological quality assurance program (VQA) at Chicago, IL, that had been contracted by the WHO-sponsored HIV proficiency testing program (30) .
DBS and plasma collection and storage. Plasma was harvested through separation within 6 h from the time of whole-blood collection in EDTA-treated anticoagulant Vacutainer tubes (Becton, Dickinson, San Jose, CA) and stored at Ϫ60°C to Ϫ80°C. DBS were prepared by pipetting 50 l of whole blood onto each of 5 spots on a 903 Whatman filter paper card (Schleicher & Schuell, Keene, NH). Filter papers were dried overnight in a clean biosafety cabinet and then placed individually in an airimpermeable zip-lock bag containing desiccants and a humidity indicator and stored at Ϫ30°C.
Nucleic acid extraction from plasma and dried blood spots. RNA from plasma was extracted using the FDA-approved ViroSeq HIV-1 genotyping system (Abbott Molecular, Abbott Park, IL) extraction protocol and the QIAamp viral RNA minikit (Qiagen Inc., Chatsworth, CA) for the in-house HIV-1 genotyping assay according to the manufacturer's instructions. Total nucleic acid (TNA) from DBS was extracted using a modified NucliSENS silica-based boom method (bioMérieux, Inc., Durham, NC) (29) . Briefly, two 6-mm spots from each patient sample were cut and added into a tube containing 0.9 ml NucliSENS lysis buffer (bioMérieux, Inc., Durham, NC) and incubated at room temperature for 2 h under gentle rotation. After incubation, the tube was centrifuged for 2 min at 1,500 ϫ g, and the supernatant was transferred into new 2-ml tubes. Nucleic acid was then extracted according to the manufacturer's instructions, eluted using 60 l of elution buffer, and stored at Ϫ80°C until use.
HIV-1 drug resistance genotyping. HIV-1 genotyping was performed at the Kenya Medical Research Institute (KEMRI)/CDC HIV laboratory, which has been accredited as a National Drug Resistance Laboratory by the WHO HIV/ResNet group.
ViroSeq HIV-1 genotyping system. The FDA-approved ViroSeq assay amplifies an 1.8-kb fragment covering the entire protease region and codons 1 to 335 of the reverse transcriptase (RT) region. This assay has an amplification detection sensitivity of 2,000 RNA copies/ml of plasma and a DR-associated mutation (DRM) detection sensitivity and specificity of 99.65% and 99.95%, respectively (35) . Drug resistance genotyping was performed according to the manufacturer's instructions, and DR interpretations were conducted using both the ViroSeq HIV-1 genotyping system software, V2.6, and the Stanford genotyping resistance interpretation algorithm (http://sierra2.stanford.edu/sierra/servlet/JSierra) to allow for comparison with the in-house assay.
In-house genotyping assay. The in-house assay amplifies a 1,084-bp fragment of the HIV-1 pol gene encoding amino acids 6 to 99 of the protease region and codons 1 to 251 of the reverse transcriptase (RT) region. This assay was developed by the CDC, Atlanta, GA, for genotyping all HIV-1 group M subtypes and circulating recombinant forms (CRFs) and has been validated using samples collected from several PEPFARsupported countries with multiple HIV-1 subtypes and CRFs (30, 32, 33) . For this validation, we followed the procedure described by Yang et al. (32) . Briefly, 15 l of nucleic acid extracts from either plasma or DBS was subjected to a one-step RT-PCR using PRTM-F1, which is a 1:1 (wt/wt) combination of two forward primers (F1a, 5=-TGAARGAITGYACTGAR AGRCAGGCTAAT, nucleotides [nt] 2057 to 2085 based on HXBII, and F1b, 5=-ACTGARAGRCAGGCTAATTTTTTAG, nt 2068 to 2092), and RT-R1 (reverse, 5=-ATCCCTGCATAAATCTGACTTGC, nt 3370 to 3348) (33; C. Yang, Z. Zhou, J. R. DeVos, and N. Wager, U.S. patent application 61/504,522) and the SuperScript III one-step RT-PCR system with Platinum Taq high-fidelity polymerase according to the manufacturer's protocol (Invitrogen, Carlsbad, CA). For the nested PCR, 4 l of the RT-PCR product was then used with the inner primers PRT-F2 (forward, 5=-CTTTARCTTCCCTCARATCACTCT, nt 2243 to 2266) and RT-R2 (reverse, 5=-CTTCTGTATGTCATTGACAGTCC, nt 3326 to 3304) (32, 33) to yield an approximately 1.1-kb amplicon. Sequencing was then performed using six overlapping primers, and sequences were analyzed using the ABI 3100 genetic analyzer. Confirmation of base-calling and sequence editing were conducted using the Sequencher V4.5 (Genecodes) software. DR interpretation was performed using the Stanford genotyping drug resistance interpretation algorithm (v4.2.6) (http://sierra2.stanford.edu /sierra/servlet/JSierra) and using the International AIDS Society (IAS) 2011 mutation list (36) for confirmation.
Assay validation. Performance characteristics of this in-house assay were determined using the WHO/HIV ResNet guidelines for validation of in-house genotyping assays, which circumvent the lack of standard or reference methods for evaluating genotyping performance of DR assays (31) . This included assessment of accuracy, precision, reproducibility, and amplification sensitivity as minimal requirements; linearity and sensitivity, though not assessed in this validation, are also considered.
Accuracy. To assess accuracy, 53 plasma and 52 DBS sample sequences obtained from the in-house assay were compared to the plasma sample sequences obtained from ViroSeq. Accuracy was determined by the degree of concordance between the 66 DRMs identified by ViroSeq and the in-house assay based on the IAS 2011 mutation list (36) .
Sensitivity. Sensitivity was assessed using 68 samples with VL ranges from 253 to 3,264,850 copies/ml, and the genotyping sensitivity is defined as the VL copy ranges at which Ն95% of the samples were successfully genotyped.
Precision and reproducibility. Precision was assessed using 10 samples with 3 to 5 replicates (5 samples with 5 replicates and 5 samples with 3 replicates), and the reproducibility was determined using 12 samples with at least 2 replicates (5 samples with 5 replicates and 7 duplicate samples). In addition, seven DBS replicates from a 14-member proficiency testing panel from VQA at Chicago, IL, were used to assess the reproducibility for DBS specimens. The replicates in the panel had been shipped under two different temperature conditions. The reproducibility test was performed by two technicians and in some cases utilizing different kit lots. Both precision and reproducibility were determined by the degree of concordance of DR-associated mutations as well as the degree of nucleotide sequence identity. Contribution of proviral DNA from DBS. The frequency of amplification of proviral DNA from DBS was investigated using the in-house assay on eight samples with VLs ranging from 15,508 to 3,264,850 copies/ ml. These 8 samples were run in the presence and absence of the RT-PCR murine leukemia virus (MuLV) enzyme.
Phylogenetic analysis. Phylogenetic analysis was performed using the neighbor-joining method in MEGA4 software (37) . The evolutionary distances were computed using the maximum composite likelihood method in units of the number of base substitutions per site. The tree was then generated by the neighbor-joining method from a nucleotide alignment of 751 positions devoid of gaps, and tree topology was confirmed by bootstrapping analysis using 1,000 replicates. Pairwise alignment to assess nucleotide sequence identity between matched plasma and DBS and those plasma sequences obtained from the ViroSeq assay was performed using the EMBOSS pairwise alignment tool (http://www.ebi.ac.uk/Tools/psa /emboss_needle/) in the needle global method for whole-length alignment (with default gap-penalty values).
Statistical analysis. The sensitivity and specificity of the in-house assay for both plasma and DBS were assessed against the ViroSeq system on 66 DRMs as identified in the IAS 2011 mutation list (36) . Quantitative variables are expressed as means Ϯ standard deviations (SDs) unless otherwise stated. The McNemar test was then used to assess for significance in the discordant mutations between the in-house and the ViroSeq assays for both sample types. Precision and reproducibility were assessed using the Cohen kappa statistic. Agreement was interpreted as weak (0.400 Ͼ Ն 0.200), moderate (0.600 Ͼ Ն 0.400), strong (0.800 Ͼ Ն 0.600), nearly perfect (1.00 Ͼ Ն 0.800), and perfect ( ϭ 1.000). Sample size was estimated using Buderer's formula (38) with the following assumptions: HIVDR prevalence of 9.3% based on a previous study in Kenya (39) , anticipated sensitivity equivalent to that obtained with the ViroSeq system of 99.65 (35) , and a two-sided test with an alpha value of 0.05 and a precision value of 0.05. A minimum sample size of 60 was then required in order to obtain a sensitivity equivalent to that of the ViroSeq system. Quality control and assurance. The quality of the test runs was ensured by the inclusion of positive and negative controls in each run. Sequence quality was confirmed by using the WHO sequence quality assessment tool (SQUAT) (40) to screen ambiguous nucleotides, frameshifts, insertions, and deletions of the sequences. In addition, ambiguous and atypical amino acids, stop codons, and frameshifts were also screened at the amino acid level. SQUAT was also used to check for cross-contamination by calculating pairwise genetic distances which were further crosschecked by the PAUP tool (41) . The KEMRI/CDC HIV research laboratory, where the analysis was performed, participates twice a year in external quality assurance (EQA) programs offered by VQA and the College of American Pathologists (CAP) for HIV plasma genotyping for both the in-house and ViroSeq assays. At the time that this study was conducted, the performances of all the proficiency testing panels were satisfactory. The laboratory is also accredited with the ISO 15189 standard and by WHO ResNet for HIVDR genotyping.
Ethical considerations. Ethical review committees of the Kenya Medical Research Institute (KEMRI) and the Institutional Review Board of the U.S. Centers for Disease Control and Prevention (CDC), Atlanta, GA, approved this study. All mothers in the KiBS study provided written informed consent that included parental consent for their infants.
Nucleotide sequence accession numbers. Sequences from this study were submitted to GenBank, and their accession numbers are JQ914045 to JQ914103.
RESULTS

Viral load determination.
Among the 68 plasma samples, the mean plasma VL was 330,855 copies/ml with a median of 58,187 copies/ml, ranging from 253 to 3,264,850 copies/ml. Of these, 44 had VLs of Ͼ10,000 copies/ml (median, 374,074), 13 ranged from 1,000 to 10,000 copies/ml (median, 4,040), and the remaining 11 had Ͻ1,000 copies/ml (median, 632).
Plasma genotyping sensitivity. Of the 68 plasma samples used to assess genotyping sensitivity, 100% (95% confidence interval [CI], 93.5 to 100) of all the 44 samples with VLs of Ͼ10,000 were genotyped by both assays. All the 13 samples with VLs between 1,000 and 10,000 copies/ml were genotyped with the in-house assay (100%; 95% CI, 80.7 to 100), and 8 (61.5%; 95% CI, 36.1 to 83.1) were genotyped with the ViroSeq assay. For those 11 samples with VLs of Ͻ1,000 copies/ml, the in-house assay was able to genotype 7 (63.6%; 95% CI, 36.2 to 85.9) while 1 (9.1%) was genotyped by the ViroSeq system (Table 1) .
DBS genotyping sensitivity. After establishing better sensitivity for plasma samples with lower VL measurements in the inhouse assay than in the ViroSeq assay, the in-house assay was then used to assess genotyping sensitivity using the matched 44 DBS samples. All the 44 DBS samples (100%; 95% CI, 93.5 to 100) with VLs of Ͼ10,000 copies/ml were genotyped by the in-house assay. In addition, 7 (53.8%; 95% CI, 29.1 to 77.3) of the 13 DBS samples with VLs between 1,000 and 10,000 copies/ml were also genotyped, while only 1 of the 11 DBS samples with VLs of Ͻ1,000 copies/ml was genotyped ( Table 1) .
Concordance of the two assays in detecting drug resistanceassociated mutations in plasma samples. The accuracy in detecting DRMs in plasma was determined by using the 53 sequences generated by the ViroSeq system. Two hundred thirty-four DRMs were observed in these 53 sequences, including 68 DRMs in the RT gene and one major and 165 minor mutations in the protease M184V  M184V  M184V  1-0317-8v8  M36I, I62V, I64V  M36I, I62V, I64V  M36I, I62V, I64V  Y181C, M184V  Y181C, M184V  Y181C, M184V  1-0317-8v12  M36I, I62V, I64V  M36I, I62V, I64V  M36IV, I62V, I64V  K70KR, Y181C, M184V  K70KR, Y181C, M184V  Y181C, M184V  1-0357-6v8  M36I, H69K  M36I, H69K  M36I, H69K  M184V, G190A  M184V, G190AG  M184V, G190A  1-0357-6v11  M36I, D60E, H69K  M36I, D60E, H69K  M36I, D60E, H69K  A98AG, K103S, M184V,  G190A, T215Y   A98AG, K103S, M184V,  G190A, T215Y   A98AG, K103S, M184V,  G190A, T215Y  1-0360-1v7  G16E, K20R, M36I,  I62V, H69K   G16E, K20R, M36I,  I62V, H69K G16E, K20R, M36I, I62V, H69K
M184V
M184V M184V
1- 0360-1v12  G16E, K20R, M36I,  I62V, H69K   G16E, K20R, M36I,  I62V, H69K   G16E, K20R, M36I,  I62V, H69K   M184MV   1-0410-4v7  M36I, L63P, H69K  M36I, L63P, H69K  M36I, L63P, H69K  M184MV, T215Y  M184MV, T215Y  M184MV, T215Y  1-0410-4v9  M36I, L63P, H69K  M36I, L63P, H69K  M36I, L63P, H69K  T215D  T215D  T215D  1-0437-5v7  M36I, L63P, H69K  M36I, L63P, H69K  M36I, L63P, H69K  M184IV  M184V  M184V  1-0437-5v11  M36I, L63P, H69K  M36I, L63P, H69K  M36I, L63P, H69K (Continued on following page) Tables 2 and 3 ). Of the four discordant DRMs between the two assays, three were due to mixtures in the RT gene. M184IV and M184MV were detected as mixtures in the ViroSeq system but were nonmixture mutations in the in-house assay (M184V). In contrast, G190AG was detected as a mixture in the in-house assay, but it was a nonmixture in the ViroSeq system (G190A). The one remaining discordant mutation was a minor mutation (G16E) in the protease gene, which was missed by the in-house assay. None of these discordant DRMs were of clinical significance when the sequences were analyzed with the HIValg program using the HIVdb v6. (Table 3) . Statistical analyses using the McNemar test on paired results for DRMs also supported the excellent performance of the in-house assay compared to the ViroSeq system ( 2 ϭ 1.80, P ϭ 0.375). The excellent performance by the in-house assay was further supported by stratification analysis of DRMs for sensitivity and specificity (sensitivity 2 ϭ 4, P ϭ 0.125, and specificity 2 ϭ 1.0, P ϭ 1.0). At the nucleotide level, the mean nucleotide sequence identity was 99.5% for the in-house assay compared to the ViroSeq system. The minor differences observed in sequence identity were mainly caused by mixture bases. We identified 126 mixture base differences among the 53 sequences analyzed; of these, 93 (74%) were detected by the inhouse assay and 86 (70%) were detected by the ViroSeq system.
Concordance of the two assays in detecting drug resistance mutations in DBS samples. Based on the satisfactory results obtained with the in-house assay in comparison with the ViroSeq system as well as the higher sensitivity in genotyping plasma samples with lower VLs with the in-house assay, we next genotyped and analyzed the 52 matched DBS samples using the in-house assay only and compared the genotyping results with those obtained from plasma samples by the ViroSeq system. Compared to sequences obtained from plasma samples using the ViroSeq system, the in-house assay gave a sensitivity of 96.54% (95% CI, 95.93 to 97.15) in DRM detection (Tables 2 and 3) . A total of 231 mutations were observed in the ViroSeq system. Of these, 223 were identified in DBS sequences by the in-house assay. Among the eight discordant DRMs, five occurred in the RT gene, four of which were caused by mixtures (Y181CY, K103KN, T215FIST, and MI84IMV) while the remaining one (K70KR) was not detected in the DBS sample by the in-house assay. The remaining three discordant mutations were detected in the protease gene, two of which occurred as mixtures at minor DR positions (K20KR and M36IV) while the other one was absent (G16E) in the inhouse assay. In addition, one extra DRM (Y181CY) was present only in one DBS sample. Despite the DRM detection differences, they were not clinically significant even for the patient with the Y181CY mutation since this patient had already had a K013KN mutation which led to high-level resistance to nonnucleoside reverse transcriptase inhibitors (NNRTI). Pairwise comparison of nucleotide substitution at DRM sites was also highly concordant for DBS with only 12 (1.7%) nonsynonymous substitutions. Similar to plasma, the in-house assay also gave near-perfect specificity (Table  3) . McNemar test analysis on paired results for DRM detection confirmed the excellent concordant results ( 2 ϭ 5.44, P ϭ 0.04) and great sensitivity and specificity ( 2 ϭ 8, P ϭ 0.008, and 2 ϭ 1.0, P ϭ 1.0), respectively. As expected, at the nucleotide level, the in-house assay also gave excellent mean nucleotide identity compared to the plasma ViroSeq system (99.5%). The minor differences from the McNemar test as well as nucleotide sequence identity were caused by mixture bases, of which the in-house assay using DBS was able to detect 79 of 126 (63%), compared to 70% for the ViroSeq system. Precision and reproducibility. Using the WHO criteria for DBS genotyping method validation, the in-house assay demonstrated a high precision and reproducibility in both DBS and plasma specimen types (Table 4) . Overall agreement for precision was nearly perfect with a kappa score of 0.974 (95% CI, 0.960 to 0.989) for plasma and 0.967 (95% CI, 0.960 to 0.968) for DBS. The mean nucleotide sequence identity score for precision was 99.4% Ϯ 0.33% in plasma and 99.2% Ϯ 0.59% in DBS. Similar results were also obtained in the reproducibility assessment, where the kappa score was nearly perfect: 0.975 (95% CI, 0.956 to 0.980) for plasma and 0.992 (95% CI, 0.991 to 0.995) for DBS. The mean nucleotide sequence identity was 99.3% Ϯ 0.35% for plasma and 99.1% Ϯ 0.59% for DBS.
Frequency of proviral DNA amplification from DBS. We also assessed the amplification contribution of proviral DNA in the TNA obtained from DBS using 8 samples with VLs ranging from 15,508 to 3,264,850 copies/ml. These 8 samples were run in the presence and absence of the RT-PCR MuLV enzyme. In the presence of the reverse transcription enzyme, the pol gene was successfully amplified in all eight samples, but only one sample with a higher VL (3,264,850 copies) could be amplified in the absence of the RT-PCR enzyme.
HIV-1 subtype analysis. Of the 64 newly obtained sequences, 49 were obtained from independent participants and the remaining 15 were obtained at different time points from these participants. Of the 49 samples, 36 were subtype A1 (73.5%), 4 were D (8.2%), 2 were C (4.1%), and 1 was G (2.0%) while 6 (12.2%) were recombinants: 4 CRF10_CD and 2 AD recombinants (Fig. 1) .
Comparative analysis of cost and total hands-on time between the two assays using plasma and DBS samples. Table 5 describes the hands-on time and cost of the different steps involved in the HIVDR testing process, from sample collection to generating results. The cost included reagents and disposables based on 2011 U.S. dollars plus the cost for major equipment maintenance. Fixed costs, such as purchasing equipment and software, personnel, and other logistics, such as those of storage, transportation, and external quality assurance (EQA), were omitted. The cost of running the in-house assay using DBS specimens was $110. 05, that for the in-house assay using plasma specimens was $113.33, and that for the ViroSeq system using plasma specimens was $278.31. In addition, the in-house assay using plasma required the least hands-on time, ϳ16 h 30 min, compared to ϳ17 h 10 min for ViroSeq and ϳ24 h 20 min for the in-house assay using DBS, which required the longest hands-on time due to the manual extraction procedure.
DISCUSSION
We observed excellent concordance of DRM detections in plasma and DBS by the in-house genotyping assay compared to the ViroSeq assay and confirmed the previous report on the excellent performance of this assay (32, 33) . The overall sensitivity and specificity of the in-house assay in detecting DRMs were 98.29% and 99.97% for plasma and 96.54% and 99.97% for DBS, respectively. The findings from this study affirm previous reports that DBS specimens offer an excellent alternative sample type for HIV genotyping for HIVDR tests (13, 29, 32, (42) (43) (44) (45) (46) . This study further demonstrates their utility and feasibility in a resource-limited setting for use in HIVDR monitoring and surveillance combined with a less costly and subtype-independent in-house genotyping assay. The overall genotyping efficiency rate for the in-house assay was 94% compared to 78% by the ViroSeq system. The relatively higher genotyping rate for the in-house assay on plasma specimens may be attributed to the shorter fragment target (1.1 versus 1.8 kb) as well as the inclusion of a nested PCR step. However, this shorter amplicon has no effect on the interpretation of the known clinically relevant DRMs described in the IAS 2011 mutation list for the protease and RT regions (36) .The overall genotyping rate for DBS specimens using the in-house assay was moderate (76%). However, when only those DBS specimens with VLs of Ն1,000 copies/ml were considered according to the WHO recommendation for ART patient monitoring (47) , the genotyping rate was greatly improved (89.5%). The lower-than-expected DBS genotyping rate might result in the lower input for TNA extraction in the current study, since we used only two 6-mm discs, which are equivalent to 32 l of whole blood. A previous study by Masciotra et al. (13) showed that TNA amplification from lower-VL samples can be achieved from DBS by using 2 complete spots (about 100 l). This was, however, not feasible in this analysis due to the depletion of some of the samples. In fact, the moderate success rate despite lower initial sample input may be a reflection of a higher sensitivity of the in-house assay. Apart from the lower ini- tial input, DBS genotyping efficiency may also be dependent on the storage conditions; in this case, the DBS samples had been stored for a period of up to 4 years under optimal conditions of Ϫ30°C. This demonstrates the integrity of the DBS samples in preserving the viral genetic materials for a long period under optimal storage conditions and is consistent with the findings from the work of Masciotra et al. (13) . This is vital in HIVDR monitoring surveys in resource-limited settings where testing is usually performed either in batched samples at the centralized genotyping laboratories within the country or in regional laboratories outside the country in some situations. The sensitivity and specificity of the in-house assay in detecting DRMs were highly concordant with those obtained in the ViroSeq system for both plasma and DBS. The discordant DRMs detected between the in-house and ViroSeq on both DBS and plasma were mainly caused by mixture bases at the DRM sites. These differences, however, were not of clinical significance, as genotypic algorithms infer the presence of resistance for a synonymous mixture mutation in the same way as they do for a complete mutation.
Another important requirement in method validation is the ability to produce accurate results within a run or between runs under similar assay conditions. The in-house assay assessed using the WHO guidelines for genotyping method validation demonstrated both good intra-and interrun comparisons as well as excellent performance in proficiency test panels for both plasma and DBS. This further confirmed a possible concordance of results if this assay is adopted for use in other laboratories in resourcelimited settings. In fact, the assay has been implemented in the Ethiopian national DR laboratory and the laboratory has been accredited by the WHO ResNet group as a National DR Laboratory (NDRL) (http://www.who.int/hiv/topics/drugresistance /technical_information/en/index.html).
The high concordance of the DRMs detected by the ViroSeq commercial assay and in-house assay (both plasma and DBS) suggests the utility of this assay in both HIVDR surveillance and monitoring. Twenty-five of the samples used in the analysis were obtained from mothers experiencing virological failures (plasma VLs of Ն1,000 copies/ml) in the KiBS trial of prevention of mother-tochild transmission (PMTCT). The HIVDR status of these mothers had been assessed in real time during the trial using the ViroSeq system; thus, confirmation of the DRM detection using the inhouse assay on both plasma and DBS suggests the clinical utility of this assay as an HIVDR monitoring tool using both sample types. However, due to the contribution of proviral DNA from peripheral blood mononuclear cells (PBMCs) in DBS, DBS is not recommended for use in long-term ART-experienced patients, as the detected DRMs may not be a full reflection of the circulating viruses but may reflect archived ones (31) . Archived viruses in the DNA have been reported to have different mutation patterns from those of circulating viruses, especially with ART-experienced persons (25, 29, 45) . As a result, genotyping from DBS which contain both the proviral DNA and free circulating RNA viruses is expected to give mutation patterns different from those of plasma in ART-experienced persons in the case of the presence of archived mutations. In this study, we observed minimal proviral contributions with only two discordant major mutations: one present in DBS but missing in plasma and vice versa. Of interest was the low frequency of proviral DNA amplification; only 1 of the 8 samples was amplified in the absence of an RT enzyme, with the amplified sample having a very high VL of Ͼ3.6 million copies/ml. This may suggest that genotyping from DBS involves mainly the free circulating viral RNA rather than the archived DNA provirus. However, the use of DBS in long-term ART-experienced patients should be made with caution, as the samples in this analysis were obtained from patients who were on ART for Ͻ1 year.
The ability to genotype multiple HIV-1 subtypes and CRFs is essential for any genotyping assay in sub-Saharan Africa where multiple subtypes and CRFs exist (32, (48) (49) (50) . This is specifically important since the two FDA-approved assays were developed and evaluated for use with subtype B viruses (23) . Previous studies using the in-house assay have shown its suitability as a broadly sensitive genotyping assay which was able to genotype HIV subtypes C, B, CRF 01 AE and 02 AG, A, and CRF 07 and 08 BC (32, 33) . From this analysis, we further affirm its broad subtype sensitivity, especially for subtypes A and D, which are also the predominant HIV strains in Kenya. It is important to note that the ViroSeq system also gave a satisfactory performance in genotyping the different virus strains in this study. However, the lower DBS sensitivity reported before (13) may restrict its utility in resourcelimited settings for HIVDR monitoring surveys due to logistical constraints for collecting plasma specimens.
One of the reasons that the HIVDR genotyping test has not become a routine service is the high cost associated with HIVDR monitoring. In this study, we performed analysis on the cost associated with the two assays using the 2011 market values in U.S. dollars. Cost assessments of the in-house assay against the ViroSeq system showed that genotyping of DBS or plasma with the inhouse assay could reduce the HIVDR testing cost by about 60%.
This study had some limitations. First, our sample size was relatively small, although it met the calculated sample size for our study purpose. Another limitation of this study is the DBS collection procedure, which was inherited from the original study design, for which the DBS from infants had not been collected by either finger or heel pricks. However, studies using DBS collected from infants by heel/finger pricks are under way, which will add the needed data for the feasibility of using DBS collected by heel/ finger pricks for HIVDR testing. Despite the limitations of the study, we believe that there are several strengths. (i) The use of the recently developed WHO guidelines in the validation process not only increases the confidence of the performance of the assay but also serves to ease the adoption by other laboratories in resourcelimited settings. (ii) This validation was conducted under real field setup conditions, and it was a true reflection of how this assay could be performed in resource-limited settings. (iii) The imple- a The cost was estimated based on U.S. dollars at the 2011 market values. The estimated costs also included the costs to run control specimens in each run and equipment maintenance but excluded fixed costs, personnel costs, and other logistics, such as storage, transportation, and enrollment in EQA programs, which are vital for the quality-assured genotyping results.
mentation of the in-house assay in another resource-limited country and further attainment of WHO ResNet accreditation as mentioned above are another testimony that if vigorous implementation procedures are followed, then the low-cost in-house assay, like the one that we validated here, can be successfully implemented in resource-limited settings. Other considerations like having well-trained, qualified, and competent personnel and meeting the minimal infrastructure requirement as well as participation in external proficiency programs should also be in place.
In conclusion, this study demonstrates the excellent performance of a lower-cost in-house genotyping assay for both plasma and DBS specimens for use in HIVDR surveillance and ART patient monitoring. This assay would be particularly appropriate for use in resource-limited settings with DBS specimens. These findings are of particular interest due to the increased need for HIVDR genotyping in resource-limited settings in the era of increasing demand for ARV usage in treating HIV-infected patients as well as treatment for prevention.
